Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Sodium-Glucose Transporter 2 Inhibitors/therapeutic use"'
Autor:
Dapa-Ckd Trial Committees, David C. Wheeler, John J.V. McMurray, C. David Sjöström, Peter Rossing, Glenn M. Chertow, Niels Jongs, Anna Maria Langkilde, Hiddo J.L. Heerspink, Robert D. Toto, Ricardo Correa-Rotter, Investigators, Bergur V. Stefánsson, Tom Greene
Publikováno v:
Lancet Diabetes & Endocrinology, 9(11), 743-754. ELSEVIER SCIENCE INC
BACKGROUND: Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagliflozin on the rate of change
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7777b1dcd5c00a7f5f10476884f5566f
https://doi.org/10.1016/s2213-8587(21)00242-4
https://doi.org/10.1016/s2213-8587(21)00242-4
Autor:
Elaine Butterly, Lili Wei, Amanda I Adler, Saleh A M Almazam, Khalid Alsallumi, Luke A K Blackbourn, Sofia Dias, Peter Hanlon, Katherine Hughes, Jim Lewsey, Robert Lindsay, Stuart McGurnaghan, John Petrie, David Phillippo, Naveed Sattar, Laurie A Tomlinson, Nicky Welton, Sarah Wild, David McAllister
Publikováno v:
Butterly, E, Wei, L, Adler, A I, Almazam, S A, Alsallumi, K, Blackbourn, L, Dias, S, Peter, H, Hughes, K A, Lewsey, J, Lindsay, R S, McGurnaghan, S, Petrie, J R, Phillippo, D, Sattar, N A, Tomlinson, L, Welton, N J, Wild, S H & McAllister, D A 2022, ' Calibrating a network meta-analysis of diabetes trials of sodium glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population : a systematic review protocol ', BMJ Open, vol. 12, no. 10, 066491, pp. e066491 . https://doi.org/10.1136/bmjopen-2022-066491
IntroductionParticipants in randomised controlled trials (trials) are generally younger and healthier than many individuals encountered in clinical practice. Consequently, the applicability of trial findings is often uncertain. To address this, resul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0969065cc95310742d6794321e8173e1
https://pubmed.ncbi.nlm.nih.gov/36302574
https://pubmed.ncbi.nlm.nih.gov/36302574
Publikováno v:
Revue medicale suisse, vol. 18, no. 795, pp. 1710-1716
High blood pressure (HBP) is common in diabetic patients and significantly increases complications of diabetes and cardiovascular risk. It is therefore particularly important to routinely screen and treat HBP in these patients. Blood pressure targets
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1900::0f701514eb540acc5fd04c4c580e97a1
https://serval.unil.ch/notice/serval:BIB_B533CB301DE1
https://serval.unil.ch/notice/serval:BIB_B533CB301DE1
Autor:
Johan Jendle, Paresh Dandona, John Xu, Nayyar Iqbal, Enrico Repetto, Markus F. Scheerer, Steven V. Edelman, Per-Henrik Groop, Fredrik Thoren, Moshe Phillip, Pieter Gillard, Chantal Mathieu
Publikováno v:
The Lancet Diabetes & Endocrinology. 8:845-854
Summary Background The DEPICT-1 and DEPICT-2 studies showed that dapagliflozin as an adjunct to insulin in individuals with inadequately controlled type 1 diabetes improved glycaemic control and bodyweight, without increase in risk of hypoglycaemia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00f7846f46b1b29ed6f481ec3393eac5
https://doi.org/10.1016/s2213-8587(20)30280-1
https://doi.org/10.1016/s2213-8587(20)30280-1
Autor:
Oliver Schnell, Tadej Battelino, Richard Bergenstal, Matthias Blüher, Michael Böhm, Frank Brosius, Richard D. Carr, Antonio Ceriello, Thomas Forst, Francesco Giorgino, Bruno Guerci, Hiddo J. L. Heerspink, Baruch Itzhak, Linong Ji, Mikhail Kosiborod, Nebojša Lalić, Michael Lehrke, Nikolaus Marx, Michael Nauck, Helena W. Rodbard, Giuseppe M. C. Rosano, Peter Rossing, Lars Rydén, Francesca Santilli, Petra-Maria Schumm-Draeger, Per Olav Vandvik, Tina Vilsbøll, Christoph Wanner, Carol Wysham, Eberhard Standl
Publikováno v:
Schnell, O, Battelino, T, Bergenstal, R, Blüher, M, Böhm, M, Brosius, F, Carr, R D, Ceriello, A, Forst, T, Giorgino, F, Guerci, B, Heerspink, H J L, Itzhak, B, Ji, L, Kosiborod, M, Lalić, N, Lehrke, M, Marx, N, Nauck, M, Rodbard, H W, Rosano, G M C, Rossing, P, Rydén, L, Santilli, F, Schumm-Draeger, P-M, Vandvik, P O, Vilsbøll, T, Wanner, C, Wysham, C & Standl, E 2022, ' Report from the CVOT Summit 2021 : new cardiovascular, renal, and glycemic outcomes ', Cardiovascular Diabetology, vol. 21, no. 1, 50 . https://doi.org/10.1186/s12933-022-01481-0
Cardiovascular diabetology 21, 50 (2022). doi:10.1186/s12933-022-01481-0
Cardiovascular Diabetology, 21:50. BioMed Central Ltd.
Cardiovascular diabetology 21, 50 (2022). doi:10.1186/s12933-022-01481-0
Cardiovascular Diabetology, 21:50. BioMed Central Ltd.
Cardiovascular diabetology 21, 50 (2022). doi:10.1186/s12933-022-01481-0
Published by BioMed Central, London
Published by BioMed Central, London
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9d83661eb396006bdb2429ffbd233bc
https://curis.ku.dk/portal/da/publications/report-from-the-cvot-summit-2021(989b36e6-8c9d-4ef0-b4d5-83b0e07c4633).html
https://curis.ku.dk/portal/da/publications/report-from-the-cvot-summit-2021(989b36e6-8c9d-4ef0-b4d5-83b0e07c4633).html
Autor:
Niels Jongs, Bergur V. Stefánsson, Ricardo Correa-Rotter, Robert D. Toto, John J.V. McMurray, Tom Greene, Dapa-Ckd Trial Committees, C. David Sjöström, Anna Maria Langkilde, Hiddo J.L. Heerspink, David C. Wheeler, Glenn M. Chertow, Investigators, Peter Rossing
Publikováno v:
Lancet Diabetes & Endocrinology, 9(11), 755-766. ELSEVIER SCIENCE INC
BACKGROUND: Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes and norm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b89091bdd4249d265893bbdc171c8e7e
https://research.rug.nl/en/publications/c2af467f-022b-4ad1-a4f9-5caab2e93272
https://research.rug.nl/en/publications/c2af467f-022b-4ad1-a4f9-5caab2e93272
Autor:
Khunti, Kamlesh, Kosiborod, Mikhail, Kim, Dae Jung, Kohsaka, Shun, Lam, Carolyn S.P., Goh, Su Yen, Chiang, Chern En, Shaw, Jonathan, Cavender, Matthew A., Tangri, Navdeep, Franch-Nadal, Josep, Holl, Reinhard W., Jørgensen, Marit Eika, Norhammar, Anna, Eriksson, Johan G., Zaccardi, Francesco, Karasik, Avraham, Magliano, Dianna J., Thuresson, Marcus, Chen, Hungta, Wittbrodt, Eric, Bodegård, Johan, Surmont, Filip, Fenici, Peter, Wilding, John P., Carstensen, Bendix, Kendrick, Rachel, Belli, Wesley, Wittbrodt, Eric T., Noguchi, Yusuke, Andersson-Sundell, Karolina
Publikováno v:
Khunti, K, Kosiborod, M, Kim, D J, Kohsaka, S, Lam, C S P, Goh, S Y, Chiang, C E, Shaw, J, Cavender, M A, Tangri, N, Franch-Nadal, J, Holl, R W, Jørgensen, M E, Norhammar, A, Eriksson, J G, Zaccardi, F, Karasik, A, Magliano, D J, Thuresson, M, Chen, H, Wittbrodt, E, Bodegård, J, Surmont, F, Fenici, P, Kosiborod, M, Cavender, M A, Wilding, J P, Khunti, K, Norhammar, A, Carstensen, B, Holl, R W, Lam, C S P, Kendrick, R, Belli, W, Wittbrodt, E T, Franch-Nadal, J, Noguchi, Y, Karasik, A, Tangri, N, Kohsaka, S, Kim, D J, Shaw, J, Andersson-Sundell, K, Goh, S Y, Chiang, C E, Eriksson, J G, Zaccardi, F, Fenici, P, Bodegård, J & on behalf of the CVD-REAL Investigators and Study Group 2021, ' Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents : analysis of CVD-REAL data ', Cardiovascular Diabetology, vol. 20, no. 1, 159 . https://doi.org/10.1186/s12933-021-01345-z
Cardiovascular Diabetology, 20(1):159. BioMed Central Ltd.
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-15 (2021)
Cardiovascular Diabetology
CARDIOVASCULAR DIABETOLOGY
Cardiovascular Diabetology, 20(1):159. BioMed Central Ltd.
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-15 (2021)
Cardiovascular Diabetology
CARDIOVASCULAR DIABETOLOGY
Background Randomized, controlled cardiovascular outcome trials may not be fully representative of the management of patients with type 2 diabetes across different geographic regions. We conducted analyses of data from the multinational CVD-REAL cons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4763cb21c00d98032e57f90498b8508
https://doi.org/10.1186/s12933-021-01345-z
https://doi.org/10.1186/s12933-021-01345-z
Autor:
Evgeny Moshkovich, Kārlis Trušinskis, Guntram Schernthaner, Marju Past, Katarina Lalic, Susanne Kaser, Agnė Abraitienė, Gabriela Radulian, Janusz Gumprecht, Martin Prázný, Alexander S. Ametov, Zsolt Gaàl, Avraham Karasik, Ivan Tkáč, Boris Mankovsky, Andrej Janež, Lea Duvnjak
Publikováno v:
Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-9 (2019)
Cardiovascular Diabetology
Cardiovascular diabetology, London : BioMed Central, 2019, vol. 18, no. 1, art. no. 115, p. 2461-2498
Cardiovascular Diabetology
Cardiovascular diabetology, London : BioMed Central, 2019, vol. 18, no. 1, art. no. 115, p. 2461-2498
EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abaca1091153e7f4b6d344fa0c211417
http://link.springer.com/article/10.1186/s12933-019-0920-3
http://link.springer.com/article/10.1186/s12933-019-0920-3
Autor:
Finn Gustafsson, Emil L. Fosbøl, Mikael Kjær Poulsen, Christian Tuxen, Caroline Kistorp, Morten Schou, Lars Videbæk, Ida Gustafsson, Peter H. Frederiksen, Lars Køber, Jesper Jensen, Niels Eske Bruun, Massar Omar, Jacob E. Møller
Publikováno v:
Trials, Vol 20, Iss 1, Pp 1-8 (2019)
Jensen, J, Omar, M, Kistorp, C, Poulsen, M K, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Fosbøl, E, Bruun, N E, Videbæk, L, Frederiksen, P H, Møller, J E & Schou, M 2019, ' Empagliflozin in heart failure patients with reduced ejection fraction : a randomized clinical trial (Empire HF) ', Trials, vol. 20, 374 . https://doi.org/10.1186/s13063-019-3474-5
Jensen, J, Omar, M, Kistorp, C, Poulsen, M K, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Fosbøl, E, Bruun, N E, Videbæk, L, Frederiksen, P H, Møller, J E & Schou, M 2019, ' Empagliflozin in heart failure patients with reduced ejection fraction : a randomized clinical trial (Empire HF) ', Trials, vol. 20, no. 1, 374 . https://doi.org/10.1186/s13063-019-3474-5
Trials
Jensen, J, Omar, M, Kistorp, C, Poulsen, M K, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Fosbøl, E, Bruun, N E, Videbæk, L, Frederiksen, P H, Møller, J E & Schou, M 2019, ' Empagliflozin in heart failure patients with reduced ejection fraction : A randomized clinical trial (Empire HF) ', Trials, vol. 20, 374 . https://doi.org/10.1186/s13063-019-3474-5
Jensen, J, Omar, M, Kistorp, C, Poulsen, M K, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Fosbøl, E, Bruun, N E, Videbæk, L, Frederiksen, P H, Møller, J E & Schou, M 2019, ' Empagliflozin in heart failure patients with reduced ejection fraction : a randomized clinical trial (Empire HF) ', Trials, vol. 20, 374 . https://doi.org/10.1186/s13063-019-3474-5
Jensen, J, Omar, M, Kistorp, C, Poulsen, M K, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Fosbøl, E, Bruun, N E, Videbæk, L, Frederiksen, P H, Møller, J E & Schou, M 2019, ' Empagliflozin in heart failure patients with reduced ejection fraction : a randomized clinical trial (Empire HF) ', Trials, vol. 20, no. 1, 374 . https://doi.org/10.1186/s13063-019-3474-5
Trials
Jensen, J, Omar, M, Kistorp, C, Poulsen, M K, Tuxen, C, Gustafsson, I, Køber, L, Gustafsson, F, Fosbøl, E, Bruun, N E, Videbæk, L, Frederiksen, P H, Møller, J E & Schou, M 2019, ' Empagliflozin in heart failure patients with reduced ejection fraction : A randomized clinical trial (Empire HF) ', Trials, vol. 20, 374 . https://doi.org/10.1186/s13063-019-3474-5
Background Data from recent cardiovascular outcome trials in patients with type 2 diabetes (T2D) suggest that sodium-glucose cotransporter 2 (SGLT2) inhibitors can prevent development of heart failure (HF) and prolong life in patients without HF. Ong
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4c6304528bc49f4a5df6af158cfe1ff
http://link.springer.com/article/10.1186/s13063-019-3474-5
http://link.springer.com/article/10.1186/s13063-019-3474-5
Publikováno v:
Revue medicale suisse, vol. 17, no. 740, pp. 1034-1038
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs which offer cardiovascular (CV) and renal benefits. They are currently indicated as first-line treatments of type 2 diabetes mellitus (T2DM) in patients with CV disease, high CV r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1900::68472c38c8f1eb8f3f7a8a91d41b1767
https://serval.unil.ch/resource/serval:BIB_7FA860CBBECC.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_7FA860CBBECC.P001/REF.pdf